Is there a role for PORT in a N1+ NSCLC patient who refuses chemotherapy after lobectomy?

A few caveats to consider - is the patient refusing adjuvant chemo, or are there competing risks (cardiac, age etc) that may attenuate the absolute benefit of adjuvant chemo?

EGFR / ALK status ? PD-1/PD-L1 status? (there are adjuvant trials evaluating other systemic options)

In the absence of other op...